The trial, led by researchers at UCL and UCLH, found that just nine weeks of treatment with pembrolizumab before surgery led to strong and lasting responses in patients with stage two or three colorectal cancer. No Cancer Recurrence After Nearly…
Continue reading with a subscription
This article is available to subscribers. Subscribe to read it in full, or sign in if you already have an account.